Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer

被引：39

作者：

Blaquier, Juan Bautista ^{[1
]}

Ortiz-Cuaran, Sandra ^{[2
]}

Ricciuti, Biagio ^{[3
]}

Mezquita, Laura ^{[4
,5
,6
]}

Cardona, Andres Felipe ^{[7
,8
,9
]}

Recondo, Gonzalo ^{[1
,10
]}

机构：

[1] Ctr Med Educ & Clin Res CEMIC, Thorac Oncol Unit, Med Oncol, Buenos Aires, DF, Argentina

[2] Univ Claude Bernard Lyon 1, Univ Lyon, CNRS 5286, INSERM 1052,Ctr Leon Berard,Ctr Rech Cancerol Lyo, Lyon, France

[3] Harvard Med Sch, Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA

[4] Inst Invest Biomed August Pi Sunyer IDIBAPS, Lab Translat Genom & Targeted Therapies Solid Tum, Barcelona, Spain

[5] Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain

[6] Univ Barcelona, Dept Med, Barcelona, Spain

[7] Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia

[8] Univ Bosque, Mol Oncol & Biol Syst Res Grp Fox G, Bogota, Colombia

[9] Luis Carlos Sarmiento Angulo Canc Treatment & Res, Direct Res & Educ, Bogota, Colombia

[10] Bradford Hill Clin Res Ctr, Med Oncol Dept, Santiago, Chile

来源：

CLINICAL CANCER RESEARCH | 2023年 / 29卷 / 18期

关键词：

PHASE-II PLATFORM; ACQUIRED-RESISTANCE; PATIENTS PTS; COMBINATION OSIMERTINIB; 1ST-LINE OSIMERTINIB; PLUS OSIMERTINIB; INTERIM ANALYSIS; ADVANCED NSCLC; THERAPY; SAVOLITINIB;

D O I：

10.1158/1078-0432.CCR-22-1912

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The current landscape of targeted therapies directed against oncogenic driver alterations in non-small cell lung cancer (NSCLC) is expanding. Patients with EGFR-mutant NSCLC can derive significant benefit from EGFR tyrosine kinase inhibitor (TKI) therapy, including the third-generation EGFR TKI osimertinib. However, invariably, all patients will experience disease progression with this therapy mainly due to the adaptation of cancer cells through primary or secondary molecular mechanisms of resistance. The comprehension and access to tissue and cell-free DNA next-generation sequencing have fueled the development of innovative therapeutic strategies to prevent and overcome resistance to osimertinib in the clinical setting. Herein, we review the biological and clinical implications of molecular mechanisms of osimertinib resistance and the ongoing development of therapeutic strategies to overcome or prevent resistance.

引用

页码：3579 / 3591

页数：13

共 128 条

[1]

Ahn MJ, 2022, J THORAC ONCOL, V17, pS469

[2] Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression [J].

Aldea, Mihaela ;

Hendriks, Lizza ;

Mezquita, Laura ;

Jovelet, Cecile ;

Planchard, David ;

Auclin, Edouard ;

Remon, Jordi ;

Howarth, Karen ;

Benitez, Jose Carlos ;

Gazzah, Anas ;

Lavaud, Pernelle ;

Naltet, Charles ;

Lacroix, Ludovic ;

de Kievit, Frank ;

Morris, Clive ;

Green, Emma ;

Ngo-Camus, Maud ;

Rouleau, Etienne ;

Massard, Christophe ;

Caramella, Caroline ;

Friboulet, Luc ;

Besse, Benjamin .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) :383-391

[3] Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer [J].

Arulananda, Surein ;

Do, Hongdo ;

Musafer, Ashan ;

Mitchell, Paul ;

Dobrovic, Alexander ;

John, Thomas .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :1728-1732

[4] Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naive EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. [J].

Bauml, Joshua ;

Cho, Byoung Chul ;

Park, Keunchil ;

Lee, Ki Hyeong ;

Cho, Eun Kyung ;

Kim, Dong-Wan ;

Kim, Sang-We ;

Haura, Eric B. ;

Sabari, Joshua K. ;

Sanborn, Rachel E. ;

Nagasaka, Misako ;

Ou, Sai-Hong Ignatius ;

Minchom, Anna Rachel ;

Gomez, Jorge E. ;

Curtin, Joshua C. ;

Gao, Grace ;

Roshak, Amy ;

Thayu, Meena ;

Knoblauch, Roland Elmar ;

Spira, Alexander I. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[5] IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy [J].

Berger, Adi Jacob ;

Gigi, Elinor ;

Kupershmidt, Lana ;

Meir, Zohar ;

Gavert, Nancy ;

Zwang, Yaara ;

Prior, Amir ;

Gilad, Shlomit ;

Harush, Uzi ;

Haviv, Izhak ;

Stemmer, Salomon M. ;

Blum, Galia ;

Merquiol, Emmanuelle ;

Mardamshina, Mariya ;

Strauss, Sivan Kaminski ;

Friedlander, Gilgi ;

Bar, Jair ;

Kamer, Iris ;

Reizel, Yitzhak ;

Geiger, Tamar ;

Pilpel, Yitzhak ;

Levin, Yishai ;

Tanay, Amos ;

Barzel, Baruch ;

Reuveni, Hadas ;

Straussman, Ravid .

NATURE CANCER, 2021, 2 (10) :1055-+

[6] NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer [J].

Blakely, Collin M. ;

Pazarentzos, Evangelos ;

Olivas, Victor ;

Asthana, Saurabh ;

Yan, Jenny Jiacheng ;

Tan, Irena ;

Hrustanovic, Gorjan ;

Chan, Elton ;

Lin, Luping ;

Neel, Dana S. ;

Newton, William ;

Bobb, Kathryn L. ;

Fouts, Timothy R. ;

Meshulam, Jeffrey ;

Gubens, Matthew A. ;

Jablons, David M. ;

Johnson, Jeffrey R. ;

Bandyopadhyay, Sourav ;

Krogan, Nevan J. ;

Bivona, Trever G. .

CELL REPORTS, 2015, 11 (01) :98-110

[7] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[8] On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation [J].

Brown, Benjamin P. ;

Zhang, Yun-Kai ;

Westover, David ;

Yan, Yingjun ;

Qiao, Huan ;

Huang, Vincent ;

Du, Zhenfang ;

Smith, Jarrod A. ;

Ross, Jeffrey S. ;

Miller, Vincent A. ;

Ali, Siraj ;

Bazhenova, Lyudmila ;

Schrock, Alexa B. ;

Meiler, Jens ;

Lovly, Christine M. .

CLINICAL CANCER RESEARCH, 2019, 25 (11) :3341-3351

[9]

Camidge DR, 2021, J THORAC ONCOL, V16, pS875

[10]

Camidge DR, 2022, J CLIN ONCOL, V40

← 1 2 3 4 5 6 7 8 9 10 →